Tim Smith

Following this analysis, the conclusions provide more information on the views of potential dermatology patients on the future of their own medical images by artificial intelligence systems.

In this analysis from the UK, the DDPS led to improved pathway management which also achieved lower service demand and smaller waiting lists for dermatologists.

In this new research, different populations of Black and Latinx individuals are facing long-term impacts of air pollution in the city of Austin.

This segment of Cohen’s interview from AAD covered the other talk given by Cohen titled ‘Knowing Lichenoid Dermatoses: Common Pathways and Treatments.’

In this post-AAD interview, Cohen discusses his contribution to the presentation titled ‘Psoriasis: Modern Therapeutic Approaches.’

The results of this meta-analysis highlight the prevalence of subclinical pulmonary tuberculosis among adult patients, given the poor clinical definition of the condition.

These findings highlight the gaps in care among patients with cancer with regard to smoking assessments.

Approvals by both the FDA and the Chinese NMPA have followed recent clinical trial data on spesolimab injection in GPP patients.

These data indicate that, despite the promise held by AI in dermatological care improvement, further evaluation of training, validation, and ethical issues must be done before it is integrated.

In an announcement by Aquestive Therapeutics, these new findings demonstrated the potential of this orally-administered epinephrine treatment.

These data highlight the risk of anxiety and depression among dermatologists, with notable findings based on gender differences observed among clinicians.

James Palmer, MD, provides perspective on the FDA's decision to approve fluticasone propionate nasal spray for adults with chronic rhinosinusitis without nasal polyps.

In this post-AAD 2024 interview, Stein Gold commented on her team’s two recent sub-analyses of the phase 4 IMMpulse studies on risankizumab for psoriasis.

The results of this analysis highlight the link between patients’ experiences with pruritus intensity and the mental health difficulties such struggles place on patients.

A post-AAD 2024 discussion on the importance of tailoring acne and rosacea management to individual patients’ needs, focusing more attention on diverse skin types and backgrounds.

In this AAD 2024 interview, Bunick highlights several new findings on the use of topical isotretinoin for treatment of congenital ichthyosis.

Alexis spoke in this AAD interview about his team’s results regarding lebrikizumab for adults and adolescents with moderate-to-severe atopic dermatitis and skin of color.

These data presented at AAD 2024 highlight deuruxolitinib’s efficacy in the treatment of adults with moderate-to-severe alopecia areata.

Another segment of Silverberg’s interview at AAD 2024 featured a discussion on safety data and the larger implications of these phase 3 findings for eczema management.

This interview at AAD featured a discussion with Silverberg on nemolizumab’s efficacy and safety at Week 48 among patients with moderate-to-severe atopic dermatitis.

These study findings, presented at AAD 2024, were the results of a recent analysis conducted to assess long-term outcomes among patients with psoriasis.

In this segment of his AAD interview, Hamzavi discussed more about his team’s findings on upadacitinib as well as their implications and future in terms of research.

In this interview segment, Lebwohl discusses the implications of his team’s late-breaking data on bimekizumab for clinical practice.

In this interview at AAD 2024, Porter discussed her team’s phase 2 findings on hidradenitis suppurativa the impact of ruxolitinib cream among those with Hurley Stage I and II.

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

This AAD 2024 interview features a discussion with Lebwohl on his team’s new late-breaking data, covering long-term findings on bimekizumab.

These phase 3 findings from AAD 2024 suggest patients treated with baricitinib may continue to see scalp, eyelash, and eyebrow hair regrowth with specific dosing regimens.

In this interview at AAD 2024, Porter discusses recent data from the SUNSHINE and SUNRISE trials on secukinumab for patients with HS.

In late-breaking data from AAD 2024, treatment with the JNJ-2113 targeted oral peptide led to several notable findings regarding patients with moderate-to-severe psoriasis.

Hamzavi discusses new late-breaking data from AAD 2024, including major takeaways and safety profile after 52 weeks.